SlideShare a Scribd company logo
Gene
Therapy
Services
An ever-evolving regulatory
environment makes navigating
gene therapy products through
to clinic much more complicated
than a traditional biologic.
While manufacturing platforms and
regulatory requirements for testing
of antibodies has existed for decades,
gene therapy platforms and their
testing requirements are changing
rapidly with the progression of
products toward commercialization.
complex & evolving
environment
The regulatory pathway for gene therapies
is complex and time-intensive. As the
global market rapidly expands, the
interpretation of regulations continues
to evolve, which is why careful planning
of your safety testing program will always
be crucial to clinical success.
WuXi Advanced Therapies' integrated approach
to gene testing program design
Building the right safety testing program
requires expertise and experience in a broad
range of disciplines, including virology,
molecular biology and cell-based techniques.
meeting your challenges
Testing plan design
Custom assay development
Multiple testing methodologies
Phase-appropriate validation
Integrating data packages
Meeting aggressive milestones
Understand the goal
timelines, deliverables
Understand the product
vectors, cell lines, clinical phase
Customize to unique needs
standard or custom assays
Navigate regulatory environment
phase-specific requirements
Provide trouble-shooting
Communicate timely updates
dedicated project management
Generate high-quality data
Perform thorough data review
Deliver interpretative reports
Provide comprehensive regulatory support
Our state-of-the-art facilities provide adaptable
manufacturing and testing solutions utilizing our
integrated services. We have the capacity to support
any program from early to late stage, with the
additional resources needed to support commercial
volumes.
Our viral vector experience is second to none, and
includes the following:
• Adeno-Associated Virus (AAV) • Adenovirus
• Lentivirus • Retrovirus
Gene Therapies Testing & Manufacturing
Discovery Clinical / CommercialPre-Clinical / Development
In-Vivo
Testing
Testing
Cell & Virus
or Plasmid
Assay
Development
Safety
–––––––
Toxicology
–––––––
Biodistribution
Upstream /
Downstream
Process
Development
Custom
Assay
Development
Small-Scale
Manufacturing
Scale-Up /
Process
Optimization
Process & QC
Analytical
Validation
cGMP
Manufacturing
Product
Release /
Stability
Testing
Patient
Monitoring
Analyses
experience
Ever since the first clinical gene therapy
programs were initiated, WuXi Advanced
Therapies has been providing the technical
testing competencies and regulatory
expertise to help navigate novel biologics
from development through to late-stage
clinical trials — supporting hundreds of
successful regulatory submissions.
WuXi Advanced Therapies offers a fully integrated set of services
to support development and manufacturing of your gene therapy
product — from concept to commercialization.
WuXi Advanced Therapies’unmatched preclinical
services for gene therapy products leverage our
unique mix of scientific and regulatory expertise
in virology, bioanalytical assays and other studies.
Our staff experience, state-of-the-art facilities, and
broad understanding of advanced therapeutic
development will support your IND.
Exceptional Preclinical
Expertise
With decades of experience in biotherapeutics
testing, WuXi Advanced Therapies offers
unparalleled capacity and guidance to reduce
time to clinic. We provide the full spectrum of
testing services, including custom assay
development. As a unique single-source, fully
integrated CDMO, we support gene therapy
products from procurement to comprehensive
product testing for safety, stability and release.
Advanced Testing
Capabilities
Flexible, Commercial-Capacity
Facilities
Extensive Viral Vector
Experience
Services for Gene Therapies
Features of our process development services include:
• Dedicated specialists with pharma experience
• Programs from pre-clinical to commercial
• Upstream and downstream optimization
• Form and fill
• Scale up and scale out
Process Development
Our GMP manufacturing program provides speed and
reliability to support the rapid advance of client
timelines. We offer:
• Dedicated suites
• Clinical and commercial package options that scale
• SUS capability
• Cross-trained staff
• Coverage 7 days a week across multiple shifts
GMP Manufacturing
Our state-of-the-art facilities provide adaptable
manufacturing and testing solutions utilizing our
integrated services. We have the capacity to support
any program from early to late stage, with the
additional resources needed to support commercial
volumes.
Our viral vector experience is second to none, and
includes the following:
• Adeno-Associated Virus (AAV) • Adenovirus
• Lentivirus • Retrovirus
Gene Therapies Testing & Manufacturing
Discovery Clinical / CommercialPre-Clinical / Development
In-Vivo
Testing
Testing
Cell & Virus
or Plasmid
Assay
Development
Safety
–––––––
Toxicology
–––––––
Biodistribution
Upstream /
Downstream
Process
Development
Custom
Assay
Development
Small-Scale
Manufacturing
Scale-Up /
Process
Optimization
Process & QC
Analytical
Validation
cGMP
Manufacturing
Product
Release /
Stability
Testing
Patient
Monitoring
Analyses
experience
Ever since the first clinical gene therapy
programs were initiated, WuXi Advanced
Therapies has been providing the technical
testing competencies and regulatory
expertise to help navigate novel biologics
from development through to late-stage
clinical trials — supporting hundreds of
successful regulatory submissions.
WuXi Advanced Therapies offers a fully integrated set of services
to support development and manufacturing of your gene therapy
product — from concept to commercialization.
WuXi Advanced Therapies’unmatched preclinical
services for gene therapy products leverage our
unique mix of scientific and regulatory expertise
in virology, bioanalytical assays and other studies.
Our staff experience, state-of-the-art facilities, and
broad understanding of advanced therapeutic
development will support your IND.
Exceptional Preclinical
Expertise
With decades of experience in biotherapeutics
testing, WuXi Advanced Therapies offers
unparalleled capacity and guidance to reduce
time to clinic. We provide the full spectrum of
testing services, including custom assay
development. As a unique single-source, fully
integrated CDMO, we support gene therapy
products from procurement to comprehensive
product testing for safety, stability and release.
Advanced Testing
Capabilities
Flexible, Commercial-Capacity
Facilities
Extensive Viral Vector
Experience
Services for Gene Therapies
Features of our process development services include:
• Dedicated specialists with pharma experience
• Programs from pre-clinical to commercial
• Upstream and downstream optimization
• Form and fill
• Scale up and scale out
Process Development
Our GMP manufacturing program provides speed and
reliability to support the rapid advance of client
timelines. We offer:
• Dedicated suites
• Clinical and commercial package options that scale
• SUS capability
• Cross-trained staff
• Coverage 7 days a week across multiple shifts
GMP Manufacturing
WuXi Advanced Therapies offers a
broad selection of routinely performed
assays and the additional expertise to
develop and validate new custom
assays for your unique programs.
As a leader in gene therapy services, WuXi
Advanced Therapies provides complete support
for your gene therapy program at every stage of
development.
We offer testing services to support programs
in pre-clinical preparation for IND, and phase-
appropriate testing for clinical development,
stability and lot release. Our technical and
regulatory experts are available to design the
right testing program for your unique product.
standard
assays
Leveraging our experience in gene therapy testing,
WuXi Advanced Therapies has developed and
validated a broad selection of routinely performed
standard assays to support gene therapy programs.
These assays are effective and ready to use, saving
time and money compared to developing a new
assay from scratch. Our standard assays include a
complete range of residuals tests to monitor
by-products of the manufacturing process during
development and for lot release. These assays cover
everything from specific host cell proteins and DNA
to leached affinity column ligands, as well as empty
to full ratios of capsids.
Preclinical Services
DNA Sequencing
Raw Material Testing
Efficacy and tK/pK Studies
Risk Assessment
Extractables / Leachables Testing
Toxicology
Dose Finding (MTD) | Subacute | Subchronic | Chronic
Biodistribution
Viral vectors | Human cells
Tumorigenicity
Model development | ESC | iPSC | Adult SC | Cell lines
GMP Cell Banking & Characterization
Viral Bank Safety & Characterization
Viral Clearance
custom
assays
Because every product is different, development of
custom assays is often still required for critical testing
that addresses unique aspects of your gene therapy.
Our technical staff has the expertise to rapidly design,
develop and validate these technically challenging
assays – such as product-specific potency assays – to
keep your program moving forward. Semi-custom
assays – such as capsid identity or purity and genome
copy number – can also be validated without lengthy
transfer or development times.
Testing and Release of
GMP Vector Lots
General Characteristics
pH | Appearance | Osmolality
Content / Dose
Viral particle concentration
Vector genome titer
Vector Infectious titer by TCID50
Potency
Custom cell-based gene expression (FACS, ELISA, PCR)
Purity and Identity
Capsid protein identity and purity
Detection of Non-Packaged Transgene DNA
Residuals:
HEK293 Protein
Infectious helper virus
Host cell DNA by qPCR
Benzonase
AVB Resin
Leached Camelid Antibody Fragment
Aggregation by Dynamic Light Scattering
Total Protein Concentration
Empty:Full Capsid (OD 260/280)
Aggregation
Particulates
Purity by SDS-PAGE
Safety
Vector Genome Sequencing
Replication-competent virus: rcAAV, RCL, RCR, RCA
In vitro assay for adventitious viral contaminants
Sterility | Mycoplasma | Endotoxin | Bioburden
Patient Monitoring Testing
In vivo transgene expression | In vivo vector persistence
Custom Assays Include:
Genomic Copy by qPCR
Transgene Expression
Potency Assays
Capsid Protein Identity
Capsid Protein Purity
Infectivity & Expression Assays
Viral Clearance Validation for Clearance
of Helper Viruses
The Advanced Therapies business unit of WuXi AppTec is a
global Contract Development and Manufacturing Organization
dedicated to accelerating and transforming development, manufacturing,
and commercialization of cell, gene, and other advanced therapies.
Accelerating Progress
and Time to Market
Integrated CDMO and Testing Service Platform
advancedtherapies.com
CONNECT WITH US
WuXiATU-107-1110118

More Related Content

What's hot

Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...
Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...
Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...
MilliporeSigma
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.
MilliporeSigma
 
Article: On the Cusp of Curing Disease
Article: On the Cusp of Curing DiseaseArticle: On the Cusp of Curing Disease
Article: On the Cusp of Curing Disease
MilliporeSigma
 
Cata_Upstream_S--1526-e
Cata_Upstream_S--1526-eCata_Upstream_S--1526-e
Cata_Upstream_S--1526-eStuart Tindal
 
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
MilliporeSigma
 
Viral Risk Mitigation - A Global Regulatory Perspective
Viral Risk Mitigation - A Global Regulatory PerspectiveViral Risk Mitigation - A Global Regulatory Perspective
Viral Risk Mitigation - A Global Regulatory Perspective
MilliporeSigma
 
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
MilliporeSigma
 
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...
MilliporeSigma
 
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
MilliporeSigma
 
A Holistic Approach to Upstream Viral Safety
A Holistic Approach to Upstream Viral SafetyA Holistic Approach to Upstream Viral Safety
A Holistic Approach to Upstream Viral Safety
Merck Life Sciences
 
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Merck Life Sciences
 
Biopharma Production and Development China 2015
Biopharma Production and Development China 2015 Biopharma Production and Development China 2015
Biopharma Production and Development China 2015
Rita Barry
 
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Merck Life Sciences
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Merck Life Sciences
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
Merck Life Sciences
 
The Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio AdditionsThe Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio Additions
Merck Life Sciences
 
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisSee the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
MilliporeSigma
 

What's hot (17)

Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...
Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...
Webinar: How Biosafety Testing will Evolve to Meet the Needs of Biologics Man...
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.
 
Article: On the Cusp of Curing Disease
Article: On the Cusp of Curing DiseaseArticle: On the Cusp of Curing Disease
Article: On the Cusp of Curing Disease
 
Cata_Upstream_S--1526-e
Cata_Upstream_S--1526-eCata_Upstream_S--1526-e
Cata_Upstream_S--1526-e
 
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
 
Viral Risk Mitigation - A Global Regulatory Perspective
Viral Risk Mitigation - A Global Regulatory PerspectiveViral Risk Mitigation - A Global Regulatory Perspective
Viral Risk Mitigation - A Global Regulatory Perspective
 
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
 
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving R...
 
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
 
A Holistic Approach to Upstream Viral Safety
A Holistic Approach to Upstream Viral SafetyA Holistic Approach to Upstream Viral Safety
A Holistic Approach to Upstream Viral Safety
 
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
 
Biopharma Production and Development China 2015
Biopharma Production and Development China 2015 Biopharma Production and Development China 2015
Biopharma Production and Development China 2015
 
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
 
The Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio AdditionsThe Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio Additions
 
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisSee the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
 

Similar to Gene Therapy Services

KWS BioTest General Brochure
KWS BioTest General BrochureKWS BioTest General Brochure
KWS BioTest General BrochureValerie Vince
 
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_BrochureJane Hibberd
 
Viral Clearance Studies
Viral Clearance StudiesViral Clearance Studies
Viral Clearance Studies
Daniel Schroen, PhD
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
Covance
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
Covance
 
Testing Services
Testing ServicesTesting Services
Testing Services
Daniel Schroen, PhD
 
Cell Therapy Services
Cell Therapy ServicesCell Therapy Services
Cell Therapy Services
Daniel Schroen, PhD
 
Biodextris Presentation - New client presentation
Biodextris Presentation - New client presentationBiodextris Presentation - New client presentation
Biodextris Presentation - New client presentationJoseph Zimmermann
 
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Covance
 
Adherent Lentivirus Suspension Production & Manufacturing.pptx
Adherent Lentivirus Suspension Production & Manufacturing.pptxAdherent Lentivirus Suspension Production & Manufacturing.pptx
Adherent Lentivirus Suspension Production & Manufacturing.pptx
GenScript ProBio
 
MEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- BrochureMEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- BrochureMedWize Solutions
 
Advance Your Program in China with Fully Integrated Clinical Development Solu...
Advance Your Program in China with Fully Integrated Clinical Development Solu...Advance Your Program in China with Fully Integrated Clinical Development Solu...
Advance Your Program in China with Fully Integrated Clinical Development Solu...
Covance
 
RANDOX Company overview (4).pdf
RANDOX   Company overview (4).pdfRANDOX   Company overview (4).pdf
RANDOX Company overview (4).pdf
Marketingtechnobmed
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)Graham Wood
 
SeraCare Capabilities Overview
SeraCare Capabilities OverviewSeraCare Capabilities Overview
SeraCare Capabilities Overviewmmarsh-seracare
 
Stabicon Corporate Presentation
Stabicon Corporate PresentationStabicon Corporate Presentation
Stabicon Corporate Presentation
STABICON LIFE SCIENCE
 
Vince & Associates Brochure
Vince & Associates BrochureVince & Associates Brochure
Vince & Associates BrochureSarah Stapleton
 
Clinical Trials
Clinical TrialsClinical Trials
Clinical Trials
IEC Group of Institutions
 

Similar to Gene Therapy Services (20)

KWS BioTest General Brochure
KWS BioTest General BrochureKWS BioTest General Brochure
KWS BioTest General Brochure
 
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
 
Viral Clearance Studies
Viral Clearance StudiesViral Clearance Studies
Viral Clearance Studies
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
 
Testing Services
Testing ServicesTesting Services
Testing Services
 
Cell Therapy Services
Cell Therapy ServicesCell Therapy Services
Cell Therapy Services
 
Biodextris Presentation - New client presentation
Biodextris Presentation - New client presentationBiodextris Presentation - New client presentation
Biodextris Presentation - New client presentation
 
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...
 
Adherent Lentivirus Suspension Production & Manufacturing.pptx
Adherent Lentivirus Suspension Production & Manufacturing.pptxAdherent Lentivirus Suspension Production & Manufacturing.pptx
Adherent Lentivirus Suspension Production & Manufacturing.pptx
 
MEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- BrochureMEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- Brochure
 
Advance Your Program in China with Fully Integrated Clinical Development Solu...
Advance Your Program in China with Fully Integrated Clinical Development Solu...Advance Your Program in China with Fully Integrated Clinical Development Solu...
Advance Your Program in China with Fully Integrated Clinical Development Solu...
 
RANDOX Company overview (4).pdf
RANDOX   Company overview (4).pdfRANDOX   Company overview (4).pdf
RANDOX Company overview (4).pdf
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)
 
SeraCare Capabilities Overview
SeraCare Capabilities OverviewSeraCare Capabilities Overview
SeraCare Capabilities Overview
 
Brochure
BrochureBrochure
Brochure
 
Brochure
BrochureBrochure
Brochure
 
Stabicon Corporate Presentation
Stabicon Corporate PresentationStabicon Corporate Presentation
Stabicon Corporate Presentation
 
Vince & Associates Brochure
Vince & Associates BrochureVince & Associates Brochure
Vince & Associates Brochure
 
Clinical Trials
Clinical TrialsClinical Trials
Clinical Trials
 

More from Daniel Schroen, PhD

Reveal Biosciences Validation of NASH Mouse Model
Reveal Biosciences Validation of NASH Mouse ModelReveal Biosciences Validation of NASH Mouse Model
Reveal Biosciences Validation of NASH Mouse Model
Daniel Schroen, PhD
 
Reveal biosciences data powered pathology
Reveal biosciences data powered pathologyReveal biosciences data powered pathology
Reveal biosciences data powered pathology
Daniel Schroen, PhD
 
Cell Banking
Cell BankingCell Banking
Cell Banking
Daniel Schroen, PhD
 
Brochure Algae Engineering Kits
Brochure Algae Engineering KitsBrochure Algae Engineering Kits
Brochure Algae Engineering Kits
Daniel Schroen, PhD
 
CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...
CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...
CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...
Daniel Schroen, PhD
 
Cell Applications Inc Brochure 2017
Cell Applications Inc Brochure 2017Cell Applications Inc Brochure 2017
Cell Applications Inc Brochure 2017
Daniel Schroen, PhD
 
Primary Cell e Newsletter Issue 18 (jun 2016) Cell Applications
Primary Cell e Newsletter Issue 18 (jun 2016) Cell ApplicationsPrimary Cell e Newsletter Issue 18 (jun 2016) Cell Applications
Primary Cell e Newsletter Issue 18 (jun 2016) Cell Applications
Daniel Schroen, PhD
 
Preventing Cell Culture Contamination with Copper CO2 Incubators
Preventing Cell Culture Contamination with Copper CO2 IncubatorsPreventing Cell Culture Contamination with Copper CO2 Incubators
Preventing Cell Culture Contamination with Copper CO2 Incubators
Daniel Schroen, PhD
 
Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...
Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...
Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...
Daniel Schroen, PhD
 
Synthetic vaccine research and development
Synthetic vaccine research and developmentSynthetic vaccine research and development
Synthetic vaccine research and development
Daniel Schroen, PhD
 

More from Daniel Schroen, PhD (10)

Reveal Biosciences Validation of NASH Mouse Model
Reveal Biosciences Validation of NASH Mouse ModelReveal Biosciences Validation of NASH Mouse Model
Reveal Biosciences Validation of NASH Mouse Model
 
Reveal biosciences data powered pathology
Reveal biosciences data powered pathologyReveal biosciences data powered pathology
Reveal biosciences data powered pathology
 
Cell Banking
Cell BankingCell Banking
Cell Banking
 
Brochure Algae Engineering Kits
Brochure Algae Engineering KitsBrochure Algae Engineering Kits
Brochure Algae Engineering Kits
 
CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...
CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...
CC3TM:A Stable,Sterile Analog of Poly-D-Lysine that is Optimal for the Cultur...
 
Cell Applications Inc Brochure 2017
Cell Applications Inc Brochure 2017Cell Applications Inc Brochure 2017
Cell Applications Inc Brochure 2017
 
Primary Cell e Newsletter Issue 18 (jun 2016) Cell Applications
Primary Cell e Newsletter Issue 18 (jun 2016) Cell ApplicationsPrimary Cell e Newsletter Issue 18 (jun 2016) Cell Applications
Primary Cell e Newsletter Issue 18 (jun 2016) Cell Applications
 
Preventing Cell Culture Contamination with Copper CO2 Incubators
Preventing Cell Culture Contamination with Copper CO2 IncubatorsPreventing Cell Culture Contamination with Copper CO2 Incubators
Preventing Cell Culture Contamination with Copper CO2 Incubators
 
Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...
Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...
Using the Thermo Scientific Sorvall® WX Ultracentrifuge to Isolate Skeletal M...
 
Synthetic vaccine research and development
Synthetic vaccine research and developmentSynthetic vaccine research and development
Synthetic vaccine research and development
 

Recently uploaded

Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 

Recently uploaded (20)

Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 

Gene Therapy Services

  • 2. An ever-evolving regulatory environment makes navigating gene therapy products through to clinic much more complicated than a traditional biologic. While manufacturing platforms and regulatory requirements for testing of antibodies has existed for decades, gene therapy platforms and their testing requirements are changing rapidly with the progression of products toward commercialization. complex & evolving environment The regulatory pathway for gene therapies is complex and time-intensive. As the global market rapidly expands, the interpretation of regulations continues to evolve, which is why careful planning of your safety testing program will always be crucial to clinical success.
  • 3. WuXi Advanced Therapies' integrated approach to gene testing program design Building the right safety testing program requires expertise and experience in a broad range of disciplines, including virology, molecular biology and cell-based techniques. meeting your challenges Testing plan design Custom assay development Multiple testing methodologies Phase-appropriate validation Integrating data packages Meeting aggressive milestones Understand the goal timelines, deliverables Understand the product vectors, cell lines, clinical phase Customize to unique needs standard or custom assays Navigate regulatory environment phase-specific requirements Provide trouble-shooting Communicate timely updates dedicated project management Generate high-quality data Perform thorough data review Deliver interpretative reports Provide comprehensive regulatory support
  • 4. Our state-of-the-art facilities provide adaptable manufacturing and testing solutions utilizing our integrated services. We have the capacity to support any program from early to late stage, with the additional resources needed to support commercial volumes. Our viral vector experience is second to none, and includes the following: • Adeno-Associated Virus (AAV) • Adenovirus • Lentivirus • Retrovirus Gene Therapies Testing & Manufacturing Discovery Clinical / CommercialPre-Clinical / Development In-Vivo Testing Testing Cell & Virus or Plasmid Assay Development Safety ––––––– Toxicology ––––––– Biodistribution Upstream / Downstream Process Development Custom Assay Development Small-Scale Manufacturing Scale-Up / Process Optimization Process & QC Analytical Validation cGMP Manufacturing Product Release / Stability Testing Patient Monitoring Analyses experience Ever since the first clinical gene therapy programs were initiated, WuXi Advanced Therapies has been providing the technical testing competencies and regulatory expertise to help navigate novel biologics from development through to late-stage clinical trials — supporting hundreds of successful regulatory submissions. WuXi Advanced Therapies offers a fully integrated set of services to support development and manufacturing of your gene therapy product — from concept to commercialization. WuXi Advanced Therapies’unmatched preclinical services for gene therapy products leverage our unique mix of scientific and regulatory expertise in virology, bioanalytical assays and other studies. Our staff experience, state-of-the-art facilities, and broad understanding of advanced therapeutic development will support your IND. Exceptional Preclinical Expertise With decades of experience in biotherapeutics testing, WuXi Advanced Therapies offers unparalleled capacity and guidance to reduce time to clinic. We provide the full spectrum of testing services, including custom assay development. As a unique single-source, fully integrated CDMO, we support gene therapy products from procurement to comprehensive product testing for safety, stability and release. Advanced Testing Capabilities Flexible, Commercial-Capacity Facilities Extensive Viral Vector Experience Services for Gene Therapies Features of our process development services include: • Dedicated specialists with pharma experience • Programs from pre-clinical to commercial • Upstream and downstream optimization • Form and fill • Scale up and scale out Process Development Our GMP manufacturing program provides speed and reliability to support the rapid advance of client timelines. We offer: • Dedicated suites • Clinical and commercial package options that scale • SUS capability • Cross-trained staff • Coverage 7 days a week across multiple shifts GMP Manufacturing
  • 5. Our state-of-the-art facilities provide adaptable manufacturing and testing solutions utilizing our integrated services. We have the capacity to support any program from early to late stage, with the additional resources needed to support commercial volumes. Our viral vector experience is second to none, and includes the following: • Adeno-Associated Virus (AAV) • Adenovirus • Lentivirus • Retrovirus Gene Therapies Testing & Manufacturing Discovery Clinical / CommercialPre-Clinical / Development In-Vivo Testing Testing Cell & Virus or Plasmid Assay Development Safety ––––––– Toxicology ––––––– Biodistribution Upstream / Downstream Process Development Custom Assay Development Small-Scale Manufacturing Scale-Up / Process Optimization Process & QC Analytical Validation cGMP Manufacturing Product Release / Stability Testing Patient Monitoring Analyses experience Ever since the first clinical gene therapy programs were initiated, WuXi Advanced Therapies has been providing the technical testing competencies and regulatory expertise to help navigate novel biologics from development through to late-stage clinical trials — supporting hundreds of successful regulatory submissions. WuXi Advanced Therapies offers a fully integrated set of services to support development and manufacturing of your gene therapy product — from concept to commercialization. WuXi Advanced Therapies’unmatched preclinical services for gene therapy products leverage our unique mix of scientific and regulatory expertise in virology, bioanalytical assays and other studies. Our staff experience, state-of-the-art facilities, and broad understanding of advanced therapeutic development will support your IND. Exceptional Preclinical Expertise With decades of experience in biotherapeutics testing, WuXi Advanced Therapies offers unparalleled capacity and guidance to reduce time to clinic. We provide the full spectrum of testing services, including custom assay development. As a unique single-source, fully integrated CDMO, we support gene therapy products from procurement to comprehensive product testing for safety, stability and release. Advanced Testing Capabilities Flexible, Commercial-Capacity Facilities Extensive Viral Vector Experience Services for Gene Therapies Features of our process development services include: • Dedicated specialists with pharma experience • Programs from pre-clinical to commercial • Upstream and downstream optimization • Form and fill • Scale up and scale out Process Development Our GMP manufacturing program provides speed and reliability to support the rapid advance of client timelines. We offer: • Dedicated suites • Clinical and commercial package options that scale • SUS capability • Cross-trained staff • Coverage 7 days a week across multiple shifts GMP Manufacturing
  • 6. WuXi Advanced Therapies offers a broad selection of routinely performed assays and the additional expertise to develop and validate new custom assays for your unique programs. As a leader in gene therapy services, WuXi Advanced Therapies provides complete support for your gene therapy program at every stage of development. We offer testing services to support programs in pre-clinical preparation for IND, and phase- appropriate testing for clinical development, stability and lot release. Our technical and regulatory experts are available to design the right testing program for your unique product. standard assays Leveraging our experience in gene therapy testing, WuXi Advanced Therapies has developed and validated a broad selection of routinely performed standard assays to support gene therapy programs. These assays are effective and ready to use, saving time and money compared to developing a new assay from scratch. Our standard assays include a complete range of residuals tests to monitor by-products of the manufacturing process during development and for lot release. These assays cover everything from specific host cell proteins and DNA to leached affinity column ligands, as well as empty to full ratios of capsids. Preclinical Services DNA Sequencing Raw Material Testing Efficacy and tK/pK Studies Risk Assessment Extractables / Leachables Testing Toxicology Dose Finding (MTD) | Subacute | Subchronic | Chronic Biodistribution Viral vectors | Human cells Tumorigenicity Model development | ESC | iPSC | Adult SC | Cell lines GMP Cell Banking & Characterization Viral Bank Safety & Characterization Viral Clearance
  • 7. custom assays Because every product is different, development of custom assays is often still required for critical testing that addresses unique aspects of your gene therapy. Our technical staff has the expertise to rapidly design, develop and validate these technically challenging assays – such as product-specific potency assays – to keep your program moving forward. Semi-custom assays – such as capsid identity or purity and genome copy number – can also be validated without lengthy transfer or development times. Testing and Release of GMP Vector Lots General Characteristics pH | Appearance | Osmolality Content / Dose Viral particle concentration Vector genome titer Vector Infectious titer by TCID50 Potency Custom cell-based gene expression (FACS, ELISA, PCR) Purity and Identity Capsid protein identity and purity Detection of Non-Packaged Transgene DNA Residuals: HEK293 Protein Infectious helper virus Host cell DNA by qPCR Benzonase AVB Resin Leached Camelid Antibody Fragment Aggregation by Dynamic Light Scattering Total Protein Concentration Empty:Full Capsid (OD 260/280) Aggregation Particulates Purity by SDS-PAGE Safety Vector Genome Sequencing Replication-competent virus: rcAAV, RCL, RCR, RCA In vitro assay for adventitious viral contaminants Sterility | Mycoplasma | Endotoxin | Bioburden Patient Monitoring Testing In vivo transgene expression | In vivo vector persistence Custom Assays Include: Genomic Copy by qPCR Transgene Expression Potency Assays Capsid Protein Identity Capsid Protein Purity Infectivity & Expression Assays Viral Clearance Validation for Clearance of Helper Viruses
  • 8. The Advanced Therapies business unit of WuXi AppTec is a global Contract Development and Manufacturing Organization dedicated to accelerating and transforming development, manufacturing, and commercialization of cell, gene, and other advanced therapies. Accelerating Progress and Time to Market Integrated CDMO and Testing Service Platform advancedtherapies.com CONNECT WITH US WuXiATU-107-1110118